Understanding how tuberculosis bacteria respond to treatment
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis
This study is looking into why some people with tuberculosis (TB) don’t get better with treatment and aims to find ways to make TB medicines work better for everyone, so patients can recover faster and more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10768772 on NIH RePORTER |
What this research studies
This research investigates the factors that influence the effectiveness of tuberculosis (TB) treatment, particularly focusing on why some patients experience treatment failure or relapse. By analyzing clinical samples of the TB bacteria, the researchers aim to uncover genetic and metabolic factors that affect how the bacteria respond to standard medications. The project combines expertise from multiple laboratories to develop new biomarkers that could help personalize treatment plans and identify novel drug targets to improve patient outcomes. Ultimately, the goal is to enhance the effectiveness of TB therapies and reduce the duration of treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with tuberculosis, particularly those who have experienced treatment failure or relapse.
Not a fit: Patients with non-tuberculosis infections or those who have not been diagnosed with tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatments for tuberculosis, reducing relapse rates and improving overall patient outcomes.
How similar studies have performed: Previous research has shown promise in identifying genetic factors related to drug resistance in tuberculosis, suggesting that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Sherman, David R — University of Washington
- Study coordinator: Sherman, David R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.